drugset / Trial / NCT01557647

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

NCT01557647

Phase 3 Withdrawn United Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.

Timeline

Start
2012-06
Primary completion
2015-12
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 0.6 mg/ml Inhaled